Mounting healthcare costs and growing economic pressure have payers around the globe challenged to balance budgets while ensuring quality healthcare for their patient population.
Commercial and price agreements have been a popular way to control payer costs for innovative drugs, but these arrangements are not the only options for ensuring market access. An emerging group of payers is beginning to consider alternatives to commercial arrangements through ongoing partnerships between payers and manufacturers.
This study will explore the types of payer-industry strategic partnerships that are emerging, as well as the best practices for establishing such partnerships and critical success factors pharmaceutical companies should consider.
The study will answer key questions:
- Who are the payers in each market at the national, regional, and local level?
- How do payers and industry define and conceive of partnerships?
- What is the stance of each payer segment toward partnership working?
- What are payer and industry expectations and objectives when entering partnerships?
- How do payers and industry feel that partnership outcomes should be measured?
- What types of partnerships currently exist in each market?
- What are the strengths and weaknesses of these current models?
- How viable are these current models in light of market trends?
- How are the opportunities for partnerships evolving in each market?
- What new and innovative partnership models are emerging in each market?